Sanofi, Regeneron, and Bayer are involved in new market developments, including FDA submissions regarding eczema and eye care treatments.
5 reports, 4 independent
Updated Jun 11
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 5
- Developments
- 6
- Repetition
- 20%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sanofi, Regeneron, and Bayer are involved in new market developments, including FDA submissions regarding eczema and eye care treatments.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Regeneron and Sanofi are seeking FDA approval for EYLEA HD pre-filled syringe and discussing collaboration expansion.Sub-event
Sanofi and Regeneron are leveraging co-development of Dupixent to establish royalty streams.1 source
- Regeneron, Bayer, and FDA are involved in the joint development of Eylea HD, following an FDA inspection of a third-party manufacturer.Sub-event
Sanofi, Regeneron, and Bayer are involved in new market developments, including FDA submissions regarding eczema and eye care treatments.1 source
Regeneron co-markets Dupixent with Sanofi.1 source
- FDA approved Dupixent for rare skin disease.
Keep exploring
Part of
Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.Also in this story
- Skyclarys announced its international expansion into Brazil and the U.K. on July 22, 2025.
- Organon acquired U.S. rights to TOFIDENCE from Biogen and laid off employees at its Jersey City headquarters.
- Biogen enhances patient outcomes through key drugs and therapies, while NIH studies reveal global incidence of ALS and CDC projects rising patient numbers in the U.S.
- Sooin was appointed Chief Business and Strategy Officer at Galapagos, which also announced a partnership with Gilead.
The entities involved
- FDA
-
Sanofi
company in Milan, Italy
Nothing else this week.
-
BAYER
company in Prague, Czechia
-
Regeneron Pharmaceuticals
American pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- insidermonkey.com
- yahoo.com
- Insider MonkeyEvercore ISI Maintains a Buy on Regeneron Pharmaceuticals (REGN) With a $750 PT Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best affordable growth stocks to buy. In a report released
- Motley Fool2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts Regeneron Pharmaceuticals is highly profitable and raking in free cash flow. Viking Therapeutics has multiple exc
- Unknown outlet